Need help finding what you are looking for?
Contact Us
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1463061
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1463061
Pharmacogenomics Market Share, Size, Trends, Industry Analysis Report, By Disease Area ; By Product & Service; By Technology; By Application; By End-Use; By Region.; Segment Forecast, 202
PUBLISHED:
PAGES: 118 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
The global pharmacogenomics market size is expected to reach USD 10.43 billion by 2032, according to a new study by Polaris Market Research. The report "Pharmacogenomics Market Share, Size, Trends, Industry Analysis Report, By Disease Area (Cancer, Cardiovascular, Neurological Diseases, Other Disease Areas); By Product & Service; By Technology; By Application; By End-Use; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The rise in popularity of pharmacogenomics (PGx) has accelerated advancements in precision medicine. PGx plays a crucial role in determining whether individuals respond well to specific drugs, avoiding adverse reactions, and determining optimal therapeutic doses. Widely utilized in various government programs, pharmacogenomic technologies contribute significantly to industry strength. To ensure the safety and efficacy of approved medications, the FDA mandates the inclusion of pharmacogenomic information on drug labels. Consequently, incorporating pharmacogenomics market data into pharmaceutical labeling in the United States becomes a noteworthy driver for market expansion.
The increasing prevalence of personalized care has been a significant driver in fueling the growth of the pharmacogenomics technology market. With a growing emphasis on tailoring medical treatments to individual patients, there has been a heightened recognition of the impact of genetic factors on drug response. Pharmacogenomics technologies play a crucial role in this landscape by determining genetic deviations that influence drug metabolism and efficacy.
Furthermore, market opportunities are incentivizing smaller participants to focus on developing novel tests for already licensed drugs, fostering growth in the years ahead. Collaboration and pipeline development for upcoming products are pivotal drivers in the pharmacogenomics technology market. Collaborative efforts among companies aim to identify appropriate tumor targets through the expansion of known modifications associated with inadequate DNA repair. Moreover, companies are actively engaged in developing single comprehensive tests capable of capturing a large amount of relevant content, further propelling market advancement.
Pharmacogenomics is poised with a significant market opportunity fueled by the transition from disease-focused to patient-centered treatment approaches, underpinning the era of personalized medicine. This transformative strategy enhances treatment effectiveness, mitigates side effects, and streamlines drug selection by customizing medical decisions and therapies to individual genetic profiles. Pharmacogenomic testing is increasingly acknowledged as crucial in pediatric care, psychiatry, and chronic disease management, facilitating the assessment of medication dosages and efficacy. With ongoing technical advancements and increasing awareness among both patients and healthcare professionals, genetic testing and personalized treatment plans are expected to witness a surge, revolutionizing healthcare delivery and fostering improved patient outcomes.
Pharmacogenomics Market Report Highlights
In 2023, the sequencing segment accounted for the largest market share and has significant advancements in terms of throughput, speed, and cost-effectiveness. These technological improvements have made sequencing more accessible and scalable, driving its widespread adoption in pharmacogenomics research and clinical applications.
The personalized medicine segment is expected to grow at the fastest CAGR during the forecast period. The growing availability of pharmacogenomics testing services and the integration of genomic data into clinical decision-making processes are further driving the adoption of personalized medicine approaches.
In 2023, North America dominated the largest market due to healthcare providers in the region recognizing the potential of pharmacogenomics to optimize drug therapy, reduce adverse drug reactions, and improve patient outcomes, leading to widespread adoption.
Asia Pacific is expected to grow at the fastest CAGR during the forecast period. Supportive government policies, increasing awareness among healthcare professionals and patients, and collaborations between academia, industry, and government entities are also contributing to the growth of the pharmacogenomics market in the Asia Pacific region.
The global key market players Bio-Rad Laboratories, Inc., Charles River Laboratories, Danaher Corporation, Eurofins Scientific, Illumina, Inc., IQVIA Inc, Laboratory Corporation of America Holdings, Medpace, Mesa Labs, Inc., and more.
Polaris Market Research has segmented the pharmacogenomics market report based on disease area, product & service, technology, application, end use, and region.
Pharmacogenomics, Disease Area Outlook (Revenue - USD Billion, 2019 - 2032)
- Cancer
- Cardiovascular
- Neurological Diseases
- Other Disease Areas
Pharmacogenomics, Product & Service Outlook (Revenue - USD Billion, 2019 - 2032)
- Kits & Reagents
- Sequencing Kits and Reagents
- PCR Kits and Reagents
- Microarray Kits and Reagents
- Other Kits and Reagents
- Service
Pharmacogenomics, Technology Outlook (Revenue - USD Billion, 2019 - 2032)
- Sequencing
- PCR
- Microarray
- Other Technologies
Pharmacogenomics, Application Outlook (Revenue - USD Billion, 2019 - 2032)
- Personalized Medicine
- Clinical Research
- Drug discovery & Preclinical Development
Pharmacogenomics, End Use Outlook (Revenue - USD Billion, 2019 - 2032)
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
Pharmacogenomics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Australia
- Rest of Asia Pacific
- Latin America
- Argentina
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
- Rest of Middle East & Africa
Product Code: PM4745
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Pharmacogenomics Market Insights
- 4.1. Pharmacogenomics - Industry Snapshot
- 4.2. Pharmacogenomics Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. The growing prevalence of disorders
- 4.2.1.2. Increasing investment for healthcare infrastructure
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High costs associated with research and development (R&D)
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTLE Analysis
- 4.5. Pharmacogenomics Industry Trends
- 4.6. COVID-19 Impact Analysis
5. Global Pharmacogenomics Market, by Disease Area
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 5.3. Cancer
- 5.3.1. Global Pharmacogenomics Market, by Cancer, by Region, 2019-2032 (USD Billion)
- 5.4. Cardiovascular
- 5.4.1. Global Pharmacogenomics Market, by Cardiovascular, by Region, 2019-2032 (USD Billion)
- 5.5. Neurological Diseases
- 5.5.1. Global Pharmacogenomics Market, by Neurological Diseases, by Region, 2019-2032 (USD Billion)
- 5.6. Other Disease Areas
- 5.6.1. Global Pharmacogenomics Market, by Other Disease Areas, by Region, 2019-2032 (USD Billion)
6. Global Pharmacogenomics Market, by Technology
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 6.3. Sequencing
- 6.3.1. Global Pharmacogenomics Market, by Sequencing, by Region, 2019-2032 (USD Billion)
- 6.4. PCR
- 6.4.1. Global Pharmacogenomics Market, by PCR, by Region, 2019-2032 (USD Billion)
- 6.5. Microarray
- 6.5.1. Global Pharmacogenomics Market, by Microarray, by Region, 2019-2032 (USD Billion)
- 6.6. Other Technologies
- 6.6.1. Global Pharmacogenomics Market, by Other Technologies, by Region, 2019-2032 (USD Billion)
7. Global Pharmacogenomics Market, by Product & Service
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 7.3. Kits & Reagents
- 7.3.1. Global Pharmacogenomics Market, by Kits & Reagents, by Region, 2019-2032 (USD Billion)
- 7.3.2. Sequencing Kits and Reagents
- 7.3.2.1. Global Pharmacogenomics Market, by Sequencing Kits and Reagents, by Region, 2019-2032 (USD Billion)
- 7.3.3. PCR Kits and Reagents
- 7.3.3.1. Global Pharmacogenomics Market, by PCR Kits and Reagents, by Region, 2019-2032 (USD Billion)
- 7.3.4. Microarray Kits and Reagents
- 7.3.4.1. Global Pharmacogenomics Market, by Microarray Kits and Reagents, by Region, 2019-2032 (USD Billion)
- 7.3.5. Other Kits and Reagents
- 7.3.5.1. Global Pharmacogenomics Market, by Other Kits and Reagents, by Region, 2019-2032 (USD Billion)
- 7.4. Service
- 7.4.1. Global Pharmacogenomics Market, by Service, by Region, 2019-2032 (USD Billion)
8. Global Pharmacogenomics Market, by Application
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 8.3. Personalized Medicine
- 8.3.1. Global Pharmacogenomics Market, by Personalized Medicine, by Region, 2019-2032 (USD Billion)
- 8.4. Clinical Research
- 8.4.1. Global Pharmacogenomics Market, by Clinical Research, by Region, 2019-2032 (USD Billion)
- 8.5. Drug discovery & Preclinical Development
- 8.5.1. Global Pharmacogenomics Market, by Drug discovery & Preclinical Development, by Region, 2019-2032 (USD Billion)
9. Global Pharmacogenomics Market, by End Use
- 9.1. Key Findings
- 9.2. Introduction
- 9.2.1. Global Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 9.3. Academic & Research Institutes
- 9.3.1. Global Pharmacogenomics Market, by Academic & Research Institutes, by Region, 2019-2032 (USD Billion)
- 9.4. Pharmaceutical & Biotechnology Companies
- 9.4.1. Global Pharmacogenomics Market, by Pharmaceutical & Biotechnology Companies, by Region, 2019-2032 (USD Billion)
- 9.5. Contract Research Organizations
- 9.5.1. Global Pharmacogenomics Market, by Contract Research Organizations, by Region, 2019-2032 (USD Billion)
10. Global Pharmacogenomics Market, by Geography
- 10.1. Key findings
- 10.2. Introduction
- 10.2.1. Pharmacogenomics Market Assessment, By Geography, 2019-2032 (USD Billion)
- 10.3. Pharmacogenomics Market - North America
- 10.3.1. North America: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.3.2. North America: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.3.3. North America: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.3.4. North America: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.3.5. North America: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.3.6. Pharmacogenomics Market - U.S.
- 10.3.6.1. U.S.: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.3.6.2. U.S.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.3.6.3. U.S.: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.3.6.4. U.S.: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.3.6.5. U.S.: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.3.7. Pharmacogenomics Market - Canada
- 10.3.7.1. Canada: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.3.7.2. Canada.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.3.7.3. Canada: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.3.7.4. Canada: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.3.7.5. Canada: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.4. Pharmacogenomics Market - Europe
- 10.4.1. Europe: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.4.2. Europe.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.4.3. Europe: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.4.4. Europe: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.4.5. Europe: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.4.6. Pharmacogenomics Market - UK
- 10.4.6.1. UK: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.4.6.2. UK.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.4.6.3. UK: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.4.6.4. UK: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.4.6.5. UK: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.4.7. Pharmacogenomics Market - France
- 10.4.7.1. France: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.4.7.2. France.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.4.7.3. France: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.4.7.4. France: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.4.7.5. France: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.4.8. Pharmacogenomics Market - Germany
- 10.4.8.1. Germany: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.4.8.2. Germany.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.4.8.3. Germany: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.4.8.4. Germany: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.4.8.5. Germany: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.4.9. Pharmacogenomics Market - Italy
- 10.4.9.1. Italy: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.4.9.2. Italy.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.4.9.3. Italy: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.4.9.4. Italy: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.4.9.5. Italy: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.4.10. Pharmacogenomics Market - Spain
- 10.4.10.1. Spain: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.4.10.2. Spain.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.4.10.3. Spain: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.4.10.4. Spain: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.4.10.5. Spain: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.4.11. Pharmacogenomics Market - Netherlands
- 10.4.11.1. Netherlands: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.4.11.2. Netherlands.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.4.11.3. Netherlands: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.4.11.4. Netherlands: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.4.11.5. Netherlands: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.4.12. Pharmacogenomics Market - Russia
- 10.4.12.1. Russia: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.4.12.2. Russia.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.4.12.3. Russia: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.4.12.4. Russia: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.4.12.5. Russia: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.5. Pharmacogenomics Market - Asia Pacific
- 10.5.1. Asia Pacific: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.5.2. Asia Pacific.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.5.3. Asia Pacific: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.5.4. Asia Pacific: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.5.5. Asia Pacific: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.5.6. Pharmacogenomics Market - China
- 10.5.6.1. China: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.5.6.2. China.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.5.6.3. China: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.5.6.4. China: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.5.6.5. China: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.5.7. Pharmacogenomics Market - India
- 10.5.7.1. India: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.5.7.2. India.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.5.7.3. India: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.5.7.4. India: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.5.7.5. India: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.5.8. Pharmacogenomics Market - Japan
- 10.5.8.1. Japan: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.5.8.2. Japan.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.5.8.3. Japan: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.5.8.4. Japan: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.5.8.5. Japan: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.5.9. Pharmacogenomics Market - Malaysia
- 10.5.9.1. Malaysia: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.5.9.2. Malaysia.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.5.9.3. Malaysia: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.5.9.4. Malaysia: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.5.9.5. Malaysia: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.5.10. Pharmacogenomics Market - Indonesia
- 10.5.10.1. Indonesia: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.5.10.2. Indonesia.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.5.10.3. Indonesia: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.5.10.4. Indonesia: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.5.10.5. Indonesia: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.5.11. Pharmacogenomics Market - South Korea
- 10.5.11.1. South Korea: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.5.11.2. South Korea.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.5.11.3. South Korea: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.5.11.4. South Korea: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.5.11.5. South Korea: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.6. Pharmacogenomics Market - Middle East & Africa
- 10.6.1. Middle East & Africa: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.6.2. Middle East & Africa: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.6.3. Middle East & Africa: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.6.4. Middle East & Africa: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.6.5. Middle East & Africa: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.6.6. Pharmacogenomics Market - Saudi Arabia
- 10.6.6.1. Saudi Arabia: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.6.6.2. Saudi Arabia.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.6.6.3. Saudi Arabia: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.6.6.4. Saudi Arabia: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.6.6.5. Saudi Arabia: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.6.7. Pharmacogenomics Market - UAE
- 10.6.7.1. UAE: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.6.7.2. UAE.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.6.7.3. UAE: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.6.7.4. UAE: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.6.7.5. UAE: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.6.8. Pharmacogenomics Market - Israel
- 10.6.8.1. Israel: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.6.8.2. Israel.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.6.8.3. Israel: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.6.8.4. Israel: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.6.8.5. Israel: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.6.9. Pharmacogenomics Market - South Africa
- 10.6.9.1. South Africa: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.6.9.2. South Africa.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.6.9.3. South Africa: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.6.9.4. South Africa: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.6.9.5. South Africa: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.7. Pharmacogenomics Market - Latin America
- 10.7.1. Latin America: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.7.2. Latin America.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.7.3. Latin America: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.7.4. Latin America: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.7.5. Latin America: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.7.6. Pharmacogenomics Market - Mexico
- 10.7.6.1. Mexico: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.7.6.2. Mexico.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.7.6.3. Mexico: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.7.6.4. Mexico: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.7.6.5. Mexico: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.7.7. Pharmacogenomics Market - Brazil
- 10.7.7.1. Brazil: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.7.7.2. Brazil.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.7.7.3. Brazil: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.7.7.4. Brazil: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.7.7.5. Brazil: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- 10.7.8. Pharmacogenomics Market - Argentina
- 10.7.8.1. Argentina: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- 10.7.8.2. Argentina.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- 10.7.8.3. Argentina: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- 10.7.8.4. Argentina: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- 10.7.8.5. Argentina: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
11. Competitive Landscape
- 11.1. Expansion and Acquisition Analysis
- 11.1.1. Expansion
- 11.1.2. Acquisitions
- 11.2. Partnerships/Collaborations/Agreements/Exhibitions
12. Company Profiles
- 12.1. Bio-Rad Laboratories, Inc
- 12.1.1. Company Overview
- 12.1.2. Financial Performance
- 12.1.3. Product Benchmarking
- 12.1.4. Recent Development
- 12.2. Charles River Laboratories
- 12.2.1. Company Overview
- 12.2.2. Financial Performance
- 12.2.3. Product Benchmarking
- 12.2.4. Recent Development
- 12.3. Danaher Corporation
- 12.3.1. Company Overview
- 12.3.2. Financial Performance
- 12.3.3. Product Benchmarking
- 12.3.4. Recent Development
- 12.4. Eurofins Scientific
- 12.4.1. Company Overview
- 12.4.2. Financial Performance
- 12.4.3. Product Benchmarking
- 12.4.4. Recent Development
- 12.5. Illumina, Inc
- 12.5.1. Company Overview
- 12.5.2. Financial Performance
- 12.5.3. Product Benchmarking
- 12.5.4. Recent Development
- 12.6. IQVIA Inc
- 12.6.1. Company Overview
- 12.6.2. Financial Performance
- 12.6.3. Product Benchmarking
- 12.6.4. Recent Development
- 12.7. Laboratory Corporation of America Holdings
- 12.7.1. Company Overview
- 12.7.2. Financial Performance
- 12.7.3. Product Benchmarking
- 12.7.4. Recent Development
- 12.8. Medpace
- 12.8.1. Company Overview
- 12.8.2. Financial Performance
- 12.8.3. Product Benchmarking
- 12.8.4. Recent Development
- 12.9. Mesa Labs, Inc
- 12.9.1. Company Overview
- 12.9.2. Financial Performance
- 12.9.3. Product Benchmarking
- 12.9.4. Recent Development
- 12.10. Novogene Co., Ltd.
- 12.10.1. Company Overview
- 12.10.2. Financial Performance
- 12.10.3. Product Benchmarking
- 12.10.4. Recent Development
- 12.11. PacBio
- 12.11.1. Company Overview
- 12.11.2. Financial Performance
- 12.11.3. Product Benchmarking
- 12.11.4. Recent Development
- 12.12. Personalis Inc
- 12.12.1. Company Overview
- 12.12.2. Financial Performance
- 12.12.3. Product Benchmarking
- 12.12.4. Recent Development
- 12.13. QIAGEN
- 12.13.1. Company Overview
- 12.13.2. Financial Performance
- 12.13.3. Product Benchmarking
- 12.13.4. Recent Development
- 12.14. PacBio
- 12.14.1. Company Overview
- 12.14.2. Financial Performance
- 12.14.3. Product Benchmarking
- 12.14.4. Recent Development
- 12.15. Personalis Inc
- 12.15.1. Company Overview
- 12.15.2. Financial Performance
- 12.15.3. Product Benchmarking
- 12.15.4. Recent Development
- 12.16. QIAGEN
- 12.16.1. Company Overview
- 12.16.2. Financial Performance
- 12.16.3. Product Benchmarking
- 12.16.4. Recent Development
Product Code: PM4745
List of Tables
- Table 1 Global Pharmacogenomics Market, by Disease Area, by Region, 2019-2032 (USD Billion)
- Table 2 Global Pharmacogenomics Market, by Technology, by Region, 2019-2032 (USD Billion)
- Table 3 Global Pharmacogenomics Market, by Product & Service, by Region, 2019-2032 (USD Billion)
- Table 4 Global Pharmacogenomics Market, by End Use, by Region, 2019-2032 (USD Billion)
- Table 5 Global Pharmacogenomics Market, by Application, by Region, 2019-2032 (USD Billion)
- Table 6 North America: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 7 North America: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 8 North America: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 9 North America: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 10 North America: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 11 U.S.: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 12 U.S.: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 13 U.S.: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 14 U.S.: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 15 U.S.: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 16 Canada: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 17 Canada: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 18 Canada: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 19 Canada: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 20 Canada: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 21 Europe: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 22 Europe: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 23 Europe: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 24 Europe: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 25 Europe: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 26 Germany: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 27 Germany: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 28 Germany: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 29 Germany: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 30 Germany: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 31 France: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 32 France: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 33 France: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 34 France: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 35 France: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 36 UK: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 37 UK: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 38 UK: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 39 UK: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 40 UK: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 41 Italy: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 42 Italy: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 43 Italy: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 44 Italy: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 45 Italy: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 46 Netherlands: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 47 Netherlands: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 48 Netherlands: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 49 Netherlands: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 50 Netherlands: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 51 Spain: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 52 Spain: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 53 Spain: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 54 Spain: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 55 Spain: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 56 Russia: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 57 Russia: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 58 Russia: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 59 Russia: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 60 Russia: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 61 Asia Pacific: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 62 Asia Pacific: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 63 Asia Pacific: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 64 Asia Pacific: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 65 Asia Pacific: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 66 China: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 67 China: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 68 China: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 69 China: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 70 China: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 71 Japan: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 72 Japan: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 73 Japan: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 74 Japan: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 75 Japan: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 76 India: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 77 India: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 78 India: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 79 India: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 80 India: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 81 Indonesia: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 82 Indonesia: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 83 Indonesia: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 84 Indonesia: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 85 Indonesia: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 86 Malaysia: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 87 Malaysia: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 88 Malaysia: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 89 Malaysia: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 90 Malaysia: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 91 South Korea: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 92 South Korea: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 93 South Korea: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 94 South Korea: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 95 South Korea: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 96 Latin America: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 97 Latin America: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 98 Latin America: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 99 Latin America: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 100 Latin America: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 101 Brazil: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 102 Brazil: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 103 Brazil: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 104 Brazil: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 105 Brazil: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 106 Mexico: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 107 Mexico: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 108 Mexico: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 109 Mexico: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 110 Mexico: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 111 Argentina: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 112 Argentina: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 113 Argentina: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 114 Argentina: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 115 Argentina: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 116 Middle East & Africa: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 117 Middle East & Africa: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 118 Middle East & Africa: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 119 Middle East & Africa: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 120 Middle East & Africa: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 121 UAE: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 122 UAE: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 123 UAE: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 124 UAE: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 125 UAE: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 126 Saudi Arabia: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 127 Saudi Arabia: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 128 Saudi Arabia: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 129 Saudi Arabia: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 130 Saudi Arabia: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 131 South Africa: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 132 South Africa: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 133 South Africa: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 134 South Africa: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 135 South Africa: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
- Table 136 Israel: Pharmacogenomics Market, by Disease Area, 2019-2032 (USD Billion)
- Table 137 Israel: Pharmacogenomics Market, by Technology, 2019-2032 (USD Billion)
- Table 138 Israel: Pharmacogenomics Market, by Product & Service, 2019-2032 (USD Billion)
- Table 139 Israel: Pharmacogenomics Market, by End Use, 2019-2032 (USD Billion)
- Table 140 Israel: Pharmacogenomics Market, by Application, 2019-2032 (USD Billion)
List of Figures
- Figure 1. Global Pharmacogenomics Market, 2019-2032 (USD Billion)
- Figure 2. Integrated Ecosystem
- Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
- Figure 4. Market by Geography
- Figure 5. Porter's Five Forces
- Figure 6. Market by Disease Area
- Figure 7. Global Pharmacogenomics Market, by Disease Area, 2021 & 2030 (USD Billion)
- Figure 8. Market by Technology
- Figure 9. Global Pharmacogenomics Market, by Technology, 2021 & 2030 (USD Billion)
- Figure 10. Market by Product & Service
- Figure 11. Global Pharmacogenomics Market, by Product & Service, 2021 & 2030 (USD Billion)
- Figure 12. Market by End Use
- Figure 13. Global Pharmacogenomics Market, by End Use, 2021 & 2030 (USD Billion)
- Figure 14. Market by Application
- Figure 15. Global Pharmacogenomics Market, by Application, 2021 & 2030 (USD Billion)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.